• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Biogen Inc.

< Previous 1 2 3 4 Next >
News headline image
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
October 06, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
September 28, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
September 24, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
September 23, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
September 18, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
September 17, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB SUPN
News headline image
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
September 02, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
September 02, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
August 29, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
August 25, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
August 25, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
August 11, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
July 30, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
July 25, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB SAGE
News headline image
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
July 21, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary
July 21, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
July 10, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
June 30, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
June 27, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
June 25, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
June 18, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
June 12, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
May 27, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
April 15, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
April 02, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
March 24, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
March 11, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
February 18, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
January 31, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
January 26, 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap